Navigation Links
Clinical Genomics Extends Strategic Alliance for Colorectal Cancer Testing Development with Quest Diagnostics
Date:7/12/2011

SYDNEY, July 12, 2011 /PRNewswire/ -- Australian biotech company Clinical Genomics Pty Ltd today announced agreement with Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, to extend a strategic alliance between the two companies related to Clinical Genomics' proprietary biomarkers for colorectal cancer and precancerous colorectal cancer tumors. Under the agreement, Quest Diagnostics will make milestone payments to Clinical Genomics for the development and validation of new molecular blood tests for the early detection of colorectal cancer. Clinical Genomics has been awarded payments after successfully achieving key research and development goals. Additional terms were not disclosed.

"There is a growing need for noninvasive blood tests that can aid the detection of colorectal cancer or precancerous polyps in the earliest, most treatable stages," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. "Quest Diagnostics is leading the industry in developing blood and fecal immunochemical tests for aiding colorectal cancer detection. By extending our alliance with Quest Diagnostics, we will continue to transition Clinical Genomics' research of colorectal cancer gene targets into clinical testing services for the large, underserved market of the United States and other countries."

Quest Diagnostics offers a broad menu of colorectal cancer tests, including the ColoVantage(TM) blood test for aiding the detection of colon cancer for patients in the United States, and the InSure(R) fecal immunochemical test (FIT), manufactured by the company's Sydney-based Enterix Inc. business and available in Australia and the United States.

Colorectal cancer is the second most common cause of cancer death of both men and women in the United States, according to the American Cancer Society. Although five-year survival for detected early-stage colorectal cancer is about 90 percent, some patients resist colonoscopy and other methods and never get screened. According to results of a recent poll co-sponsored by Quest Diagnostics, three in four people would be more likely to be screened for colon cancer if a blood test were available.

About Clinical Genomics

Clinical Genomics is a Sydney-based biotechnology company formed in 2006 to exploit the patented and patent-pending gene expression biomarkers for colorectal cancer discovered by its founders and Flinders University in 2001. Clinical Genomics continues to work closely with Flinders University and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia to advance the development of products that will improve the detection and management of colorectal neoplasia.  Additional information is available at: www.clinicalgenomics.com

Further Information:
Dr. Lindsay Collinson
Clinical Genomics Pty Ltd
Ph: +61 2 9888 9065
E: Lindsay.collinson@clinicalgenomics.com


'/>"/>
SOURCE Clinical Genomics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
2. "Pure" Human Blood Stem-Cell Discovery Opens Door to Expanding Cells for More Clinical Use
3. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
4. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
5. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
6. AltheaDx Incorporates Next-Generation Sequencing Into Its Clinical Testing Pipeline.
7. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
8. Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International
9. ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
10. ClinicalRM (formerly CRM) Awarded $97MM U.S. Army Contract to Support Military Clinical Research for the Warfighter
11. MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... ... 15, 2017 , ... Algenist is continuing to disrupt the ... cream with a patented formula, clinically proven to deliver visible firming results in ... Cream to our already innovative ELEVATE product line,” said vice president of product ...
(Date:5/12/2017)... ANN ARBOR, Mich. , May 12, 2017 /PRNewswire/ ... been selected to present at the 36th annual Michigan ... Investment Forum. GreenMark, a Delaware ... will be presenting to investors in attendance, including more ... to deliver health benefits to society through biobased targeting ...
(Date:5/11/2017)... SEATTLE, WA (PRWEB) , ... May 11, 2017 , ... ... regulatory review, is proud to announce that it has joined SMART IRB , ... The goal of SMART IRB is to ease burdens related to multi-site research and ...
(Date:5/10/2017)... ... May 10, 2017 , ... Shimadzu Scientific Instruments ... a host of technologically advanced features, resulting in a modernized instrument that improves ... yields a higher return on investment. , Engineered with the analyst in ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
Breaking Biology News(10 mins):